Navigation Links
Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Date:1/13/2009

LA JOLLA, Calif., Jan. 13 /PRNewswire/ -- Burnham Institute for Medical Research (Burnham) has signed an assay development and license agreement with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). The agreement is Burnham's first broad-based partnership with a large pharmaceutical company.

Under this multi-year agreement, Burnham will provide J&JPRD with access to high-throughput assay screening technologies to investigate certain drug targets for inflammatory diseases. Financial terms were not disclosed.

"This collaboration offers great synergies," said Dr. John Reed, Burnham President and CEO, Professor and Donald Bren Presidential Chair. "Burnham has great expertise in finding new targets and screening compounds to identify chemical leads, and I believe this collaboration will foster the discovery of drug products with real clinical potential."

About Burnham Institute for Medical Research

Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest growing research institutes in the country. The Institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its world-class capabilities in stem cell research and drug discovery technologies.

In September 2008, Burnham was awarded a prestigious six-year, $98 million Molecular Libraries Probe Production Centers Network (MLPCN) grant from the National Institutes of Health, and is one of four comprehensive small-molecule screening and discovery centers in the nation.

Burnham is a nonprofit, public benefit corporation. For more information, please visit www.burnham.org.

    Media Contacts:
    Josh Baxt
    Burnham Institute for Medical Research
    jbaxt@burnham.org
    858-795-5236

    Martina Schwarzkopf, Ph.D.
    Russo Partners, LLC
    martina.schwarzkopf@russopartnersllc.com
    212-845-4292


'/>"/>
SOURCE Burnham Institute for Medical Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. Cyntellect to Collaborate With the Burnham Institute for Medical Research
3. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
4. Neurobiological Technologies Announces Suspension of Viprinex Development
5. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
6. Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services
7. Varian, Inc. Announces Online Experience
8. Victhom announces the completion of the second phase of the apnea therapy development
9. The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates
10. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
11. Abbott Announces Earnings Guidance for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):